Metabolomics of biomarker discovery in ovarian cancer: a systematic review of the current literature

[1]  F. Markowetz,et al.  Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas. , 2016, Cancer research.

[2]  H. Gabra,et al.  Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy , 2016, Oncotarget.

[3]  Matthew Burnell,et al.  Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Sunghyouk Park,et al.  Cancer metabolomics in basic science perspective , 2015, Archives of Pharmacal Research.

[5]  V. Govorun,et al.  Proteome–Metabolome Profiling of Ovarian Cancer Ascites Reveals Novel Components Involved in Intercellular Communication* , 2014, Molecular & Cellular Proteomics.

[6]  J. Huynh,et al.  A systematic review of metabolite profiling in gestational diabetes mellitus , 2014, Diabetologia.

[7]  Peng Lee,et al.  Lipid metabolism in prostate cancer. , 2014, American journal of clinical and experimental urology.

[8]  Alexander G. Gray,et al.  Feasibility of detecting prostate cancer by ultraperformance liquid chromatography-mass spectrometry serum metabolomics. , 2014, Journal of proteome research.

[9]  G. Lou,et al.  Large‐scale profiling of metabolic dysregulation in ovarian cancer , 2014, International journal of cancer.

[10]  E. Jobard,et al.  A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. , 2014, Cancer letters.

[11]  Mark P. Styczynski,et al.  Applications of metabolomics in cancer research , 2013, Journal of carcinogenesis.

[12]  Pier Paolo Pandolfi,et al.  Cancer metabolism: fatty acid oxidation in the limelight , 2013, Nature Reviews Cancer.

[13]  K. Nicolaides,et al.  Proteomic Biomarkers of Preterm Birth Risk in Women with Polycystic Ovary Syndrome (PCOS): A Systematic Review and Biomarker Database Integration , 2013, PloS one.

[14]  Tao Zhang,et al.  Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. , 2013, Journal of proteome research.

[15]  David S. Wishart,et al.  HMDB 3.0—The Human Metabolome Database in 2013 , 2012, Nucleic Acids Res..

[16]  A. Harris,et al.  How cancer metabolism is tuned for proliferation and vulnerable to disruption , 2012, Nature.

[17]  W. Wick,et al.  Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. , 2012, Cancer research.

[18]  J. Chen,et al.  Urinary hydrophilic and hydrophobic metabolic profiling based on liquid chromatography‐mass spectrometry methods: Differential metabolite discovery specific to ovarian cancer , 2012, Electrophoresis.

[19]  R. Weiss,et al.  Urinary acylcarnitines are altered in human kidney cancer , 2012, International Journal of Cancer.

[20]  Tao Zhang,et al.  Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[21]  Ming-zhu Yin,et al.  Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform , 2012, Acta oncologica.

[22]  L. Cantley,et al.  Metabolomics of Human Cerebrospinal Fluid Identifies Signatures of Malignant Glioma* , 2012, Molecular & Cellular Proteomics.

[23]  D. Wishart.  Advances in metabolite identification. , 2011, Bioanalysis.

[24]  J. Gohagan,et al.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. , 2011, JAMA.

[25]  Sham S. Kakar,et al.  Identification of Metabolites in the Normal Ovary and Their Transformation in Primary and Metastatic Ovarian Cancer , 2011, PloS one.

[26]  Xiaohua Wu,et al.  Serum 27-nor-5β-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer. , 2011, Journal of proteome research.

[27]  Thomas Szyperski,et al.  Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe. , 2011, Journal of proteome research.

[28]  A. Jazaeri,et al.  A nomogram for estimating the probability of ovarian cancer. , 2011, Gynecologic oncology.

[29]  K. Kurz,et al.  Enhanced tryptophan degradation in patients with ovarian carcinoma correlates with several serum soluble immune activation markers. , 2011, Immunobiology.

[30]  J. Chen,et al.  Application of L-EDA in metabonomics data handling: global metabolite profiling and potential biomarker discovery of epithelial ovarian cancer prognosis , 2011, Metabolomics.

[31]  Vitor Sousa,et al.  Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. , 2011, Journal of proteome research.

[32]  E. Atkinson,et al.  A new approach for identifying patients with ovarian epithelial neoplasms based on high-resolution mass spectrometry. , 2010, American journal of clinical pathology.

[33]  M. Sawyer,et al.  Urine Metabolite Analysis Offers Potential Early Diagnosis of Ovarian and Breast Cancers , 2010, Clinical Cancer Research.

[34]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[35]  Alexander G. Gray,et al.  Rapid Mass Spectrometric Metabolic Profiling of Blood Sera Detects Ovarian Cancer with High Accuracy , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[36]  M. Porta,et al.  Methodological Deficits in Diagnostic Research Using ‘-Omics’ Technologies: Evaluation of the QUADOMICS Tool and Quality of Recently Published Studies , 2010, PloS one.

[37]  M. Hirai,et al.  MassBank: a public repository for sharing mass spectral data for life sciences. , 2010, Journal of mass spectrometry : JMS.

[38]  H. Blom,et al.  Ovarian Cyst Fluid of Serous Ovarian Tumors Contains Large Quantities of the Brain Amino Acid N-acetylaspartate , 2010, PloS one.

[39]  David S Wishart,et al.  Computational strategies for metabolite identification in metabolomics. , 2009, Bioanalysis.

[40]  H. Kajiyama,et al.  Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. , 2009, Gynecologic oncology.

[41]  Alexander G. Gray,et al.  Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines , 2009, BMC Bioinformatics.

[42]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[43]  H. Woo,et al.  Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[44]  S. Eckhardt,et al.  Clinical Applications of Metabolomics in Oncology: A Review , 2009, Clinical Cancer Research.

[45]  Marina Pollán,et al.  QUADOMICS: an adaptation of the Quality Assessment of Diagnostic Accuracy Assessment (QUADAS) for the evaluation of the methodological quality of studies on the diagnostic accuracy of '-omics'-based technologies. , 2008, Clinical biochemistry.

[46]  Feng Su,et al.  The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? , 2008, American journal of obstetrics and gynecology.

[47]  J. Wands,et al.  The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. , 2008, Cancer research.

[48]  R. Deberardinis,et al.  Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis , 2007, Proceedings of the National Academy of Sciences.

[49]  David S. Wishart,et al.  Current Progress in computational metabolomics , 2007, Briefings Bioinform..

[50]  O. Fiehn,et al.  Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. , 2006, Cancer research.

[51]  W. Weckwerth,et al.  Metabolomics: from pattern recognition to biological interpretation. , 2005, Drug discovery today.

[52]  J R Griffiths,et al.  Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. , 2005, Human molecular genetics.

[53]  P. Whiting,et al.  No role for quality scores in systematic reviews of diagnostic accuracy studies , 2005, BMC Medical Research Methodology.

[54]  Bruce D. Hammock,et al.  Metabolomics: building on a century of biochemistry to guide human health , 2005, Metabolomics.

[55]  Alan Hutson,et al.  Detection of epithelial ovarian cancer using 1H‐NMR‐based metabonomics , 2005, International journal of cancer.

[56]  Rebecca Sutphen,et al.  Lysophospholipids are potential biomarkers of ovarian cancer. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[57]  W. Jonat,et al.  Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis , 2004, Archives of Gynecology and Obstetrics.

[58]  Morris H. Baslow,et al.  N-Acetylaspartate in the Vertebrate Brain: Metabolism and Function , 2003, Neurochemical Research.

[59]  A. Falus,et al.  Histamine, Part of the Metabolome , 2003, Acta biologica Hungarica.

[60]  M. Baslow,et al.  Evidence supporting a role for N-acetyl-l-aspartate as a molecular water pump in myelinated neurons in the central nervous system An analytical review , 2002, Neurochemistry International.

[61]  N. Reo.  NMR-BASED METABOLOMICS , 2002, Drug and chemical toxicology.

[62]  U. Engelke,et al.  High‐resolution proton nuclear magnetic resonance spectroscopy of ovarian cyst fluid , 2000, NMR in biomedicine.

[63]  J. Berek,et al.  Ovarian cancer: epidemiology, biology, and prognostic factors. , 2000, Seminars in surgical oncology.

[64]  F. Sánchez-Jiménez,et al.  Histamine, polyamines, and cancer. , 1999, Biochemical pharmacology.

[65]  B. Melichar,et al.  Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[66]  A. P. Odin.  Vitamins as antimutagens: advantages and some possible mechanisms of antimutagenic action. , 1997, Mutation research.

[67]  W. Mitch,et al.  Metabolic effects of L-phenyllactate in perfused kidney, liver, and muscle. , 1980, The American journal of physiology.

[68]  O. Warburg.  On the origin of cancer cells. , 1956, Science.

[69]  N. Urban,et al.  Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors. , 2016, Gynecologic oncology.

[70]  Y. Cheng,et al.  Expanded metabolomics approach to profiling endogenous carbohydrates in the serum of ovarian cancer patients. , 2016, Journal of separation science.

[71]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[72]  Royston Goodacre,et al.  Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. , 2011, Chemical Society reviews.

[73]  J. Thigpen.  Effect of Screening on Ovarian Cancer Mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial , 2011 .

[74]  D. Raftery,et al.  Early Detection of Recurrent Breast Cancer Using Metabolite Profiling , 2010 .

[75]  B. Hammock,et al.  Mass spectrometry-based metabolomics. , 2007, Mass spectrometry reviews.

[76]  R. Bast,et al.  The CA 125 tumour-associated antigen: a review of the literature. , 1989, Human reproduction.

[77]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[78]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.